share_log

NRX Pharmaceuticals Analyst Ratings

Benzinga Analyst Ratings ·  Nov 9, 2022 19:22
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/09/2022 367.89% Ascendiant Capital → $4 Initiates Coverage On → Buy
06/30/2022 133.95% HC Wainwright & Co. → $2 Initiates Coverage On → Buy

NRX Pharmaceuticals Questions & Answers

What is the target price for NRX Pharmaceuticals (NRXP)?

The latest price target for NRX Pharmaceuticals (NASDAQ: NRXP) was reported by Ascendiant Capital on November 9, 2022. The analyst firm set a price target for $4.00 expecting NRXP to rise to within 12 months (a possible 367.89% upside). 2 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for NRX Pharmaceuticals (NRXP)?

The latest analyst rating for NRX Pharmaceuticals (NASDAQ: NRXP) was provided by Ascendiant Capital, and NRX Pharmaceuticals initiated their buy rating.

When is the next analyst rating going to be posted or updated for NRX Pharmaceuticals (NRXP)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NRX Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NRX Pharmaceuticals was filed on November 9, 2022 so you should expect the next rating to be made available sometime around November 9, 2023.

Is the Analyst Rating NRX Pharmaceuticals (NRXP) correct?

While ratings are subjective and will change, the latest NRX Pharmaceuticals (NRXP) rating was a initiated with a price target of $0.00 to $4.00. The current price NRX Pharmaceuticals (NRXP) is trading at is $0.85, which is within the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment